Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin
On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.
Shanghai Fosun Pharmaceutical Reports 1H Results
Ardelyx Announces Acceptance Of New Drug Application For Tenapanor For Hyperphosphatemia In China; Triggers $2M Milestone Payment To Ardelyx Under The Terms Of The License Agreement Between Co And Shanghai Fosun Pharmaceutical Industrial Development Co.
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, t
Market Chatter: Fosun Pharma in Talks With Beijing Over Pfizer-BioNTech's COVID-19 Vaccine; Shares Fall 4%
11:53 PM EDT, 03/24/2022 (MT Newswires) -- Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) and the Chinese government are still discussing the approval for the use of Pfizer and BioNTech's COVID-
Shanghai Fosun Pharmaceutical reports FY results
Shanghai Fosun Pharmaceutical press release (OTCPK:SFOSF): FY net profit attributable to shareholders of the listed company amounted to RMB 4,735M, representing an increase of 29.28% Y/Y.The net prof
Fosun Pharma Forms Two Funds to Invest in New Drug-Related Projects
04:09 AM EST, 11/25/2021 (MT Newswires) -- Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) formed two investment funds in a bid to invest in early-stage innovative drug projects relating to non-